Due to maintenance, the Publications.gc.ca website may operate intermittently between 5:00 am ET until 9:00 am ET on Sunday, October 22, 2017.
Cost pressure of the new hepatitis C drugs in Canada: H82-25/2016-PDF
Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada.
"The pricing, utilization and cost related to the direct-acting antivirals (DAAs) for the treatment of hepatitis C has become a critical issue for public plans, private insurers and patients. This study provides insight into the use, pricing and cost of DAAs in Canada and internationally in 2015, along with a retrospective look at the recent trends. The international analysis focuses on the PMPRB7 countries: France, Germany, Italy, Sweden, Switzerland, the United Kingdom (UK) and the United States (US). Results for the Canadian market are reported at the national level, as well as for the private and public market segments."
|Department/Agency||Patented Medicine Prices Review Board.|
|Title||Cost pressure of the new hepatitis C drugs in Canada|
|Subtitle||Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada.|
|Language||Bilingual-[English | French]|
|Electronic Document|| |
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact the authoring department to request a format other than those available.
We invite you to consult the Frequently Asked Questions page for additional information regarding the Archived Content notice.
Note: The URLs contained in this/these document(s) may no longer be functional
|Note||Caption title. At head of title: National Prescription Drug Utilization Information System.|
|Number of Pages|| p. :|
|Subject Terms||Hepatitis, Drugs, Prices|
- Date modified: